Pharma-Bio Serv Announces Results for the Quarter Ended July 31, 2025
-
End of an era: last hereditary peers exit UK parliament
-
Canada holds key rate steady, says will act if war inflation persists
-
Emery aims to write 'new chapter' in Europe with Villa
-
US Supreme Court curbs race-based voting maps in landmark ruling
-
Guerrillas claim deadly Colombia attack, say it was an 'error'
-
Trump warns Iran better 'get smart soon' and accept nuclear deal
-
UN experts urge Saudi labour practices switch before World Cup
-
Oil spikes while stocks slide ahead of US Fed rate decision
-
US Fed chief's plans in focus as central bank set to hold rates steady
-
Tuareg rebels vow Mali junta 'will fall', north will be captured
-
German inflation jumps in April as energy costs surge
-
Was PSG against Bayern the Champions League's greatest ever game?
-
UBS first-quarter profits jump 80% on investment banking
-
France's 'roadmap' to exit fossil fuels by 2050
-
Chelsea captain Millie Bright retires
-
Bangladesh measles outbreak kills over 220 children since March
-
Finnish lift maker Kone acquires German rival TKE, creating giant
-
Hungary's Magyar visits Brussels seeking to unblock EU billions
-
Diving robot explores mystery of France's deepest shipwreck
-
Thai ex-PM Thaksin to be released from prison next month
-
Welsh rugby great North to hang up his boots
-
Much-needed rains revive Iraq's fabled Mesopotamian Marshes
-
French teen in straw licking case allowed to leave Singapore
-
EU chief says Kremlin imposing 'digital Iron Curtain' on Russians
-
South Korean court hikes ex-president's sentence for obstructing justice
-
Adidas reports higher profits but warns of 'volatile' climate
-
TotalEnergies first-quarter profits surge amid Middle East war
-
Sri Lanka government 'temporarily' takes over cricket board
-
EU finds Meta failing to keep under-13s off Facebook, Instagram
-
King Charles to stress UK-US cultural, trade ties in New York
-
US judge orders Purdue Pharma to pay billions ahead of bankruptcy
-
'Jurassic Park' star Sam Neill says cancer-free after gene therapy
-
US opioid crisis victims testify at emotional Purdue Pharma hearing
-
Australian climber on record sea-to-summit Everest bid
-
Indian opposition slams Nicobar megaport plan as 'destruction'
-
Pentagon chief to testify on Iran war, peace efforts stall
-
Anxiety, resentment around AI spur violence against tech's figureheads
-
Mercedes-Benz profit slides amid cutthroat Chinese market
-
Hungary's Magyar to push post-Orban EU reset on Brussels visit
-
Going online helps Pakistan's women doctors back to work
-
Wembanyama's Spurs advance in NBA playoffs, 76ers stay alive
-
Tropical forest loss eases after record year: researchers
-
Tigres edges Nashville in CONCACAF Champions Cup first leg
-
New Zealand officials reject statue remembering Japan's sex slaves
-
King Charles, Trump toast ties despite Iran tensions
-
Japan cleaner goes viral with spa-like service for plushies
-
What we learned from cycling's Spring Classics
-
Villa, Forest revive European glory days in semi-final showdown
-
Remarkable, ramshackle Rayo chasing Conference League dream amid chaos
-
Unbeaten records on the line for Inoue-Nakatani superfight in Tokyo
NYSE - LSE
Pharma-Bio Serv Announces Results for the Quarter Ended July 31, 2025
DORADO, PUERTO RICO / ACCESS Newswire / September 15, 2025 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced that revenues for the three and nine months ended July 31, 2025 were approximately $2.0 million and $6.9, million, respectively. Revenues for the three and nine months ended July 31, 2024 were approximately $2.4 million and $7.2 million, respectively. Net loss for the three and nine months ended July 31, 2025 was approximately $0.2 million and $0.1 million, respectively, an earnings increase of approximately $0.1 million and $0.7 million when compared to the same periods last year, respectively.
"Over the past quarters, we have taken decisive steps to streamline our cost structure, prioritize core business segments, and exit less profitable areas. We believe these efforts have positioned the Company to capitalize on new opportunities with greater agility and focus. We are encouraged by the momentum building across our operations and are preparing for the immediate commencement of several significant projects. The Company remains committed to delivering long-term value to shareholders through disciplined execution," stated Mr. Sanchez Chief Executive Officer of the Company.
About Pharma-Bio Serv, Inc.
Pharma-Bio Serv services the Puerto Rico, United States, Europe and Latin America markets. Pharma-Bio Serv's core business is FDA and international agencies regulatory compliance consulting related services. The Company's global team includes leading engineering and life science professionals, quality assurance managers and directors.
Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of the U.S. federal securities laws, which statements may include information regarding the plans, intentions, expectations, future financial performance, or future operating performance of Pharma-Bio Serv. Forward-looking statements are based on the expectations, estimates, or projections of management as of the date of this earnings announcement. Although Pharma-Bio Serv's management believes these expectations, estimates, or projections to be reasonable as of the date of this earnings announcement, forward-looking statements are inherently subject to significant business risks, economic uncertainties, and competitive uncertainties, and other factors, which could cause its actual results or performance to differ materially from what may be expressed or implied in the forward-looking statements. Important factors that could cause Pharma-Bio Serv's actual results or performance to differ materially from the forward-looking statements include those set forth in the "Risk Factors" section of Pharma-Bio Serv's Annual Report on Form 10-K for the year ended October 31, 2024, and in its other filings with the Securities and Exchange Commission, which filings are available at www.sec.gov. Pharma-Bio Serv disclaims any intention or obligation to update or revise any forward-looking statements to reflect subsequent events and circumstances, except to the extent required by applicable law.
Company Contact:
Pedro J. Lasanta
Chief Financial Officer
787 278 2709
SOURCE: Pharma-Bio Serv Inc.
View the original press release on ACCESS Newswire
H.Gonzales--AT
